Pharmacogenetics of new analgesics
Authors:
- 11 May 2011
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 163 (3) , 447-460
Abstract
Patient phenotypes in pharmacological pain treatment varies between individuals, which could be partly assigned to their genotypes regarding the targets of classical analgesics (OPRM1,PTGS2) or associated signalling pathways (KCNJ6). Translational and genetic research have identified new targets, for which new analgesics are being developed. This addresses voltage‐gated sodium, calcium and potassium channels, for whichSCN9A,CACNA1B,KCNQ2andKCNQ3, respectively, are primary gene candidates because they code for the subunits of the respective channels targeted by analgesics currently in clinical development. Mutations in voltage gated transient receptor potential (TRPV) channels are known from genetic pain research and may modulate the effects of analgesics under development targeting TRPV1 or TRPV3. To this add ligand‐gated ion channels including nicotinic acetylcholine receptors, ionotropic glutamate‐gated receptors and ATP‐gated purinergic P2X receptors with most important subunits coded byCHRNA4,GRIN2BandP2RX7. Among G protein coupled receptors, δ‐opioid receptors (coded byOPRD1), cannabinoid receptors (CNR1andCNR2), metabotropic glutamate receptors (mGluR5 coded byGRM5), bradykinin B1(BDKRB1) and 5‐HT1A(HTR1A) receptors are targeted by new analgesic substances. Finally, nerve growth factor (NGFB), its tyrosine kinase receptor (NTRK1) and the fatty acid amide hydrolase (FAAH) have become targets of interest. For most of these genes, functional variants have been associated with neuro‐psychiatric disorders and not yet with analgesia. However, research on the genetic modulation of pain has already identified variants in these genes, relative to pain, which may facilitate the pharmacogenetic assessments of new analgesics. The increased number of candidate pharmacogenetic modulators of analgesic actions may open opportunities for the broader clinical implementation of genotyping information.Keywords
This publication has 175 references indexed in Scilit:
- Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter regionJournal of Human Genetics, 2010
- Polymorphisms of the HTR1a allele are linked to frontal brain electrical asymmetryBiological Psychology, 2010
- A de novo 8.8‐Mb deletion of 21q21.1–q21.3 in an autistic male with a complex rearrangement involving chromosomes 6, 10, and 21American Journal of Medical Genetics Part A, 2009
- Targeting Voltage-Gated Calcium Channels for Neuropathic Pain ManagementNeurotherapeutics, 2009
- Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?Pain, 2009
- Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genesMolecular Psychiatry, 2009
- Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependenceAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009
- Role of voltage-gated calcium channels in ascending pain pathwaysBrain Research Reviews, 2009
- Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic riskMolecular Psychiatry, 2008
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007